Trial Profile
An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tavokinogene telseplasmid (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 10 Jun 2020 Status changed from active, no longer recruiting to completed.
- 06 May 2020 Results published in the Clinical Cancer Research
- 13 Jun 2019 According to an OncoSec Medical media release, immunological data from company's biomarker program taken from the OMS-102, KEYNOTE-695 (metastatic melanoma), and KEYNOTE-890 (metastatic triple negative breast cancer) studies will be presented at World Pharma Week (WPW) 2019.